TRCT
SPRY icon

Tower Research Capital (TRC)’s ARS Pharmaceuticals SPRY Stock Holding History

Tower Research Capital (TRC)’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.6K Sell
3,441
-7,791
-69% -$67K ﹤0.01% 3272
2026
Q1 		$90.2K Buy
11,232
+10,183
+971% +$97.6K ﹤0.01% 2266
2025
Q4 		$12.2K Sell
1,049
-6,404
-86% -$62.3K ﹤0.01% 3504
2025
Q3 		$74.9K Buy
7,453
+1,169
+19% +$16.8K ﹤0.01% 2229
2025
Q2 		$110K Buy
6,284
+158
+3% +$2.28K ﹤0.01% 2306
2025
Q1 		$77.1K Sell
6,126
-39,450
-87% -$475K ﹤0.01% 1921
2024
Q4 		$481K Buy
45,576
+41,269
+958% +$578K 0.01% 1089
2024
Q3 		$62.5K Sell
4,307
-3,383
-44% -$40.2K ﹤0.01% 2594
2024
Q2 		$65.4K Buy
7,690
+7,459
+3,229% +$66.2K ﹤0.01% 2885
2024
Q1 		$2.36K Sell
231
-6,834
-97% -$51K ﹤0.01% 5060
2023
Q4 		$38.7K Sell
7,065
-28,581
-80% -$125K ﹤0.01% 3288
2023
Q3 		$135K Buy
35,646
+26,143
+275% +$172K ﹤0.01% 1743
2023
Q2 		$63.7K Sell
9,503
-198
-2% -$1.32K ﹤0.01% 2384
2023
Q1 		$64K Buy
9,701
+1,539
+19% +$11.8K ﹤0.01% 2284
2022
Q4 		$70K Buy
8,162
+1,542
+23% +$10K ﹤0.01% 2110
2022
Q3 		$35K Sell
6,620
-3,939
-37% -$19.4K ﹤0.01% 3475
2022
Q2 		$45K Sell
10,559
-9,244
-47% -$32.2K ﹤0.01% 2993
2022
Q1 		$70K Buy
19,803
+17,009
+609% +$74K ﹤0.01% 2462
2021
Q4 		$19K Sell
2,794
-1,780
-39% -$14.5K ﹤0.01% 3742
2021
Q3 		$46K Buy
4,574
+3,478
+317% +$85.8K ﹤0.01% 3035
2021
Q2 		$34K Buy
1,096
+439
+67% +$14.1K ﹤0.01% 3360
2021
Q1 		$29K Buy
+657
New +$31.1K ﹤0.01% 3589

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Tower Research Capital (TRC)'s SPRY Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its ARS Pharmaceuticals (SPRY) stake by 69% in Q2 2026, selling an estimated $67K and leaving 3,441 shares worth $27.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3272.

Tower Research Capital (TRC) first reported a position in SPRY in Q1 2021 and has held it in 22 quarters since. The position peaked at $481K in Q4 2024. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Tower Research Capital (TRC) held 3,441 shares of ARS Pharmaceuticals worth $27.6K as of Q2 2026.
  • Tower Research Capital (TRC) sold 7,791 ARS Pharmaceuticals shares in Q2 2026, an estimated $67K.
  • ARS Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3272 holding.
  • Tower Research Capital (TRC) first reported a position in ARS Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
  • Tower Research Capital (TRC)'s ARS Pharmaceuticals position peaked at $481K in Q4 2024.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.